H.C. Wainwright analyst Andrew Fein raised his price target for Seattle Genetics to $150 from $140 saying yesterday's data update from EV-103 continues to support his bullish view on the potential of EV plus pembrolizumab in treating frontline cisplatin-ineligible patients. He believes EV-103 plus pembrolizumab and chemotherapy may become the standard treatment for cisplatin-eligible patients. In light of the "highly positive" data from EV-103 study, Fein elected to add first- and second-line metastatic urothelial carcinoma opportunities in his model. He reiterates a Buy rating on Seattle Genetics.